Evidence map›Paper›PMID 36202887›Full record

ArticleScientific reports2022

HTLV infection in Brazil's second-largest indigenous reserve.

Carolina Amianti, Larissa Melo Bandeira, Gabriela Alves Cesar, Sabrina Weis-Torres, Tayana Serpa Ortiz Tanaka, Indianara Ramires Machado, Crhistinne Cavalheiro Maymone Gonçalves, Simone Simionatto, Erica Cristina Dos Santos Schnaufer, Felipe Bonfim Freitas and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Epidemiology and Clinical Outcomes of HTLV-1: A Comprehensive Narrative Review of Endemic and Nonendemic Regions.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Carolina Amianti *Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.
Larissa Melo Bandeira *Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil. larissa_m_bandeira@hotmail.com.
Gabriela Alves CesarUniversidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.
Sabrina Weis-TorresUniversidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.
Tayana Serpa Ortiz TanakaUniversidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.
Indianara Ramires MachadoFaculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
Crhistinne Cavalheiro Maymone GonçalvesUniversidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.
Simone SimionattoUniversidade Federal da Grande Dourados, Dourados, MS, Brazil.
Erica Cristina Dos Santos SchnauferUniversidade Federal da Grande Dourados, Dourados, MS, Brazil.
Felipe Bonfim FreitasInstituto Evandro Chagas, Ananindeua, PA, Brazil.
Antonio Carlos Rosário VallinotoUniversidade Federal do Pará, Belém, PA, Brazil.
Julio CrodaUniversidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.
Ana Rita Coimbra Motta-CastroUniversidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.
Universidade Federal de Mato Grosso do Sul · BRFundação Oswaldo Cruz · BRUniversidade Federal da Grande Dourados · BRInstituto Evandro Chagas · BRUniversidade de São Paulo · BRUniversidade Federal do Pará · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human T-lymphotropic viruses 1 and 2 (HTLV-1/2) have a worldwide distribution. HTLV-1 has been associated with several diseases, including an aggressive malignant disease known as adult T-cell leukemia/lymphoma and a chronic inflammatory neurological disease called HTLV-1-associated myelopathy, while HTLV-2 has not been definitively associated with diseases. HTLV-2 is most prevalent in specific groups such as injecting drug users and the indigenous population. In Brazil, most studies about HTLV in indigenous are carried out in indigenous communities from the north of the country. Mato Grosso do Sul (MS), Central Brazil, has the second-largest indigenous population in Brazil. However, there is no available data about HTLV infection in this group. We conducted the first investigation of HTLV-1/2 infection prevalence in the indigenous population from Jaguapiru and Bororó villages in Dourados City, MS, to provide the prevalence and molecular characterization of HTLV. For that, a total of 1875 indigenous participated in the study. All the serum samples were screened by an enzyme-linked immunosorbent assay commercial kit for the presence of anti-HTLV-1/2 antibodies. Positive samples were confirmed by HTLV-1/2 Western Blot assay. The HTLV-1 5'LTR region was detected by nested PCR amplification and sequenced by Sanger. Most of the study population declared belonging to Guarani-Kaiowá ethnicity (69.18%), 872 (46.51%), and 1003 (53.49%) were from Jaguapiru and Bororó villages, respectively. The median age of participants was 31 years, and 74.24% were females. Two individuals were detected with HTLV-1 (0.1%; CI 95% 0.1-0.2). The phylogenetic analysis revealed that isolates belong to the Cosmopolitan subtype and the Transcontinental subgroup (HTLV-1aA). The low HTLV-1 prevalence found in this study is similar to that observed among blood donors, and pregnant populations from Mato Grosso do Sul. The absence of HTLV-2 infection among these Brazilian indigenous communities would suggest a distinct behavior pattern from other indigenous populations in Brazil.

Indexed as

HTLV-II InfectionsHTLV-I InfectionsHuman T-lymphotropic virus 1AdultBrazilFemaleHumansHuman T-lymphotropic virus 2MalePhylogenyPregnancyPrevalence

Identifiers

PMID36202887
PMCPMC9537150
OpenAlexW4302293933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.